For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

The FDA spent more than 15 years crafting the guidelines, which are designed to do away with industry practices that downplay ...

Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of seven other antidiabetic ...

The study adds that “Similar reductions were seen across obesity status, gender, and age groups,” although “further clinical ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

Alzheimer's disease (AD) is a progressive brain disorder that gradually destroys memory and cognitive abilities, affecting ...

Semaglutide medications — such as Ozempic ... could be beneficial in preventing or slowing down the development of AD," lead author and biomedical informatics professor Rong Xu told Fox News ...

(CNN) — Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.

Semaglutide linked to significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs. HealthDay News — For patients with type 2 diabetes mellitus ...